InvestorsHub Logo
Followers 466
Posts 26935
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 79

Wednesday, 05/18/2011 10:27:15 AM

Wednesday, May 18, 2011 10:27:15 AM

Post# of 297
Sweet on Nektar Therapeutics
The biopharmaceutical firm is seeing much activity for its NKTR-102 drug.

Nektar Therapeutics (NKTR: Nasdaq) By Boenning & Scattergood ($9.95, May 16, 2011)

We are initiating coverage of Nektar Therapeutics with an Outperform rating and a target price of $15.

Based on the remarkable activity of Nektar's (ticker: NKTR) drug called NKTR-102 (made of polymer conjugated irinotecan) in advanced ovarian (platinum resistant and refractory) and breast cancers (taxane and anthracycline failures), we are not surprised that management has retained control of ...

http://online.barrons.com/article/SB50001424052970204038504576329714169261514.html?ru=yahoo&mod=yahoobarrons


surf's up......crikey



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTR News